- Coordinator
- Ludwig-Maximilians-Universitaet Muenchen, Germany
- Runs
- 1 October 2024 to 30 September 2029
- Status
- Running
- EU funding
- €8.5m
- Total cost
- €17.5m
- Partners
- 32 organisations in 12 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101165643
What the project is doing
In the project's own words, from its summary on CORDIS.
NHPig is an Innovative Health Initiative (IHI) project based on the public-private partnership of the European Union and Europe’s health industries. Its objective is to expand, share and implement biological knowledge of mini-/micropig models with the aim to reduce non-human primates (NHPs) in non-clinical safety studies. The transnational consortium includes experts in porcine medical models, veterinary pathology, computational animal science, non-clinical science, OMICs profiling, new approach methods (NAMs), as well as bioinformatics and artificial intelligence.
NHPig will i) characterise humanised minipigs, micropigs and tailored disease models, including systematic biobanking, multi-OMICs profiling, and state-of-the-art imaging modalities; ii) develop, validate and implement biosensors, medical devices, and ‘intelligent’ animal housing for automated data collection and analysis in minipig safety studies; iii) fill significant knowledge gaps in the (patho)physiology of the porcine immune system; iv) validate known toxicity and efficacy biomarkers and discover novel biomarker candidates for non-clinical safety assessment; v) overcome the shortage of laboratory tools and reagents, such as validated antibodies; vi) gain experience in using mini-/micropigs for safety testing of biologicals and new therapeutic modalities; vii) Investigate in vitro to in vivo extrapolation of liver and kidney toxicity in pigs and NHP/humans to provide a comparative link to human new approach methodologies (NAMs); and viii) provide a publicly available database and IT platform for compiling, integrating and analysing existing data in NHPs/humans with data in mini-/micropig models (existing data and data generated within the NHPig programme).
The establishment of a regulatory advisory board and an ethics- and animal welfare advisory board will expedite regulatory interactions and ensure compliance with the 3R principles. NHPig will generate the scientific basis for de-selection of NHPs in non-clinical safety assessment, which is an ethical requirement and also imperative according to EU legislation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Coordinator |
| Veterinaermedizinische Universitaet Wien | Wien | Austria | Participant |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Universiteit Antwerpen | Antwerpen | Belgium | Participant |
| Eidgenoessisches Departement Des Innern | Bern | Switzerland | Associatedpartner |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Novartis Pharma AG | Basel | Switzerland | Participant |
| Ustav Zivocisne Fyziologie a Genetiky Av Cr V.v.i. | Libechov | Czechia | Participant |
| Bayer Aktiengesellschaft | Leverkusen | Germany | Participant |
| Boehringer Ingelheim Internationalgmbh | Ingelheim | Germany | Participant |
| Boehringer Ingelheim Pharma GmbH &co Kg | Ingelheim | Germany | Associatedpartner |
| Merck Healthcare Kgaa | Darmstadt | Germany | Associatedpartner |
| Merck Kommanditgesellschaft Auf Aktien | Darmstadt | Germany | Participant |
| Sanofi-Aventis Deutschland GmbH | Frankfurt Am Main | Germany | Associatedpartner |
| Technische Universitaet Muenchen | Muenchen | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| Ellegaard Gottingen Minipigs AS | Dalmose | Denmark | Participant |
| H. Lundbeck AS | Valby | Denmark | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Charles River Laboratories France Safety Assessment | Saint-Germain-Nuelles | France | Participant |
| Etisense | Lyon | France | Participant |
| Sanofi-Aventis Recherche & Developpement | Gentilly | France | Participant |
| Biotalentum Tudasfejleszto Kft | Goedoello | Hungary | Participant |
| Mediso Orvosi Berendezes Fejleszto es Szerviz Kft. | Budapest | Hungary | Participant |
| Avantea SRL | Cremona | Italy | Participant |
| Istituto di Ricerche Biomediche Antoine Marxer RBM S.p.A. | Colleretto Giacosa | Italy | Associatedpartner |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Glaxosmithkline Research & Development Limited | London | United Kingdom | Participant |
| Labcorp Early Development Laboratories Limited | Harrogate | United Kingdom | Participant |
| Breakthrough T1d | New York | United States | Participant |
| Sanofi US Services Inc. | Cambridge, Massachusetts | United States | Associatedpartner |
| Verisim Life Inc | San Francisco | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI